Prime Medicine, Inc. (PRME): Capital Expenditures
$4.53M
Year ended 2025-12-31
$797.0K
Trailing 12 months to 2026-06-30
-34.5%
3-year compound annual growth
+48.0%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.53M | -37.9% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $7.29M | -16.4% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $8.72M | -45.8% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $16.09M | +287.8% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $4.15M | +549.5% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $639.0K | n/a | 2023-03-09, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $4.53M | -37.9% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $185.0K | -94.5% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $23.0K | n/a |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $134.0K | -42.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $532.0K | -77.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $914.0K | -51.9% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $128.0K | +392.3% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $5.95M | +715.5% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $738.0K | +97.3% |
Compare PRME, OCGN, ZEOX, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗